NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

aTyr Pharma, Inc. (ATYR) Stock Analysis

aTyr Pharma, Inc. (ATYR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ATYR

$0.50

−$0.01 (−1.39%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATYR with… →

ATYR Key Statistics

As of Sep 4, 2026
Trading
Open
$0.49
Previous Close
$0.50
Day's Range
0.49–0.51
52-Week Range
0.40–6.50
Volume
252.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.53
Valuation
Market Cap
$48.78M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
256.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$190.00K−19.15%
Net Income (FY)
−$74.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
98.09M
1-Year Return
−90.91%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.34M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ATYR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−36.53%
2025−78.37%
2024+156.74%
2023−35.62%
2022−70.68%
2021+92.53%
2020−6.95%
2019−39.95%
2018−85.83%
2017+62.79%
2016 (partial year)−34.85%

As of September 4, 2026.

ATYR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$190.00K−$74.12M−39009.5%
2024$235.00K−$64.02M−27243.8%
2023$353.00K−$50.39M−14274.5%
2022$10.39M−$45.34M−436.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$190.00K—−$77.63M−$74.12M−39009.5%
2024$235.00K—−$67.91M−$64.02M−27243.8%
2023$353.00K—−$54.92M−$50.39M−14274.5%
2022$10.39M—−$46.40M−$45.34M−436.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATYR Valuation vs Biotechnology Median

Median of 656 stocks
MetricATYRBiotechnology medianvs median
P/S ratio256.7315.2616.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values aTyr Pharma, Inc. (ATYR) at $48.78M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 58.

Over the past 52 weeks the price has ranged from $0.40 to $6.50. The most recent close on file for ATYR is $0.50, dated September 4, 2026. That is −$0.01 (−1.39%) against the previous close. The latest close sits 25.82% above that 52-week low.

Financial Health

In fiscal 2025, aTyr Pharma, Inc. reported revenue of $190.00K. Against the prior fiscal year total of $235.00K, that is a change of −19.15%. The same year closed with a net loss of $74.12M. Profit margin runs at 0%. Trailing earnings per share are −0.62.

Across the 4 fiscal years on file, revenue moves from $10.39M in 2022 to $190.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 256.73 times revenue. On price-to-sales that is 16.8 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −90.91%. Measured over 10 years, that is −35.62% a year compounded. Beta against the wider market is reported at 0.53. Daily returns over the trailing 10 years annualize to a volatility of 88.44%.

Growth & Income

The record shows no dividend for ATYR.

So far in 2026 the price is −36.53%. The strongest complete calendar year on file is 2024 at +156.74%; the weakest is 2018 at −85.83%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

aTyr Pharma, Inc. (ATYR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
aTyr Pharma, Inc. ATYR $48.78M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. aTyr Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About aTyr Pharma, Inc.

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Visit website →